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Objectives. We investigated whether patients with mild heart
failure due to left ventricular systolic dysfunction were at risk of
worsening during digoxin withdrawal.
Background. Deterioration during digoxin withdrawal is often
believed to be restricted to patients with moderate to severe
clinical evidence of heart failure. To test this hypothesis, we
studied the outcome of patients categorized by treatment assign-
ment and a clinical signs and symptoms heart failure score in two
rigorously designed clinical heart failure trials: the Prospective
Randomized Study of Ventricular Function and Efficacy of
Digoxin (PROVED) and the Randomized Assessment of Digoxin
and Inhibitors of Angiotensin-Converting Enzyme (RADIANCE)
trial.
Methods. Potential differences in treatment failure, left ventric-
ular ejection fraction and exercise capacity were evaluated in
three groups of patients: those with mild heart failure (score <22)
who were withdrawn from digoxin (Dig WD Mild); those with
moderate heart failure (score >2) who were withdrawn from
digoxin (Dig WD Moderate); and patients who continued receiv-
ing digoxin regardless of heart failure score (Dig Cont).
Results. Heart failure score at randomization did not predict
outcome during follow-up in Dig Cont-group patients. Dig WD
Mild-group patients were at increased risk of treatment failure
and had deterioration of exercise capacity and left ventricular
ejection fraction compared with that in Dig Cont-group patients
(all p < 0.01). Patients in the Dig WD Moderate group were
significantly more likely to experience treatment failure than
patients in either the Dig WD Mild or Dig Cont group (both p <
0.05).
Conclusions. Patients with systolic left ventricular dysfunction
were at risk of clinical deterioration after digoxin withdrawal
despite mild clinical evidence of congestive heart failure.
(J Am Coll Cardiol 1997;30:42–8)
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Historically, a number of controversies have surrounded the
use of digitalis in patients with heart failure. One classical
debate appears to be resolved (1). Favorable results from early
studies have been confirmed by more rigorous clinical trials
that support the role of digoxin in the treatment of patients
with heart failure who are in normal sinus rhythm rather than
atrial fibrillation (2–12). Additionally, results of the Digoxin
Investigators Group (DIG) study (13) appear to resolve two
important and persistent issues concerning digoxin efficacy.
Benefit was evident whether digoxin was withdrawn or added
to background therapy, and no adverse mortality effect was
associated with digoxin use.
These trial results draw attention to the remaining unre-
solved issues concerning digoxin therapy in heart failure. One
debate of particular clinical importance concerns the utility of
digoxin in patients with significant left ventricular dysfunction
but little or no clinical evidence of classical congestive heart
failure (14,15). The important early clinical trials of Lee et al.
(4) and Guyatt et al. (6) suggested that the favorable clinical
response to digoxin in heart failure might be restricted to
patients who had substantial clinical evidence of congestion
and shortness of breath. Since that time, digitalis has often
been considered to be ineffective in patients who, despite a
history of heart failure, are lacking significant signs and
symptoms of this syndrome at the time of presentation.
Despite the clinical importance of this issue, most efficacy
studies have not been able to specifically investigate the
therapeutic effects of digoxin in patients with mild clinical
heart failure. Small sample sizes and lack of characterization of
patient signs and symptoms limit conclusions from these
investigations (1–9). In contrast, the combined experience
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from the Prospective Randomized Study of Ventricular Func-
tion and Efficacy of Digoxin (PROVED) (10) and Randomized
Assessment of Digoxin and Inhibitors of Angiotensin-
Converting Enzyme (RADIANCE) (11) trials of digoxin with-
drawal provides a unique opportunity to further investigate
this issue. Detailed data concerning heart failure signs and
symptoms were prospectively collected in these trials before
randomization and combined into a composite heart failure
score after a modification of that of Carlson et al. (16). We
compared the outcome of patients with mild heart failure
(score #2) who were withdrawn from digoxin therapy (Dig
WD Mild) with that of patients who continued to receive
digoxin regardless of heart failure score (Dig Cont) and
patients with moderate heart failure (score .2) who were
withdrawn from digoxin (Dig WD Moderate).
Methods
Design of protocols. The PROVED (10) and RADIANCE
(11) trials shared a similar design (Fig. 1). Both studies were
multicenter, double-blind, randomized, placebo-controlled
parallel-group protocols. Each study began with an 8-week
single-blind stabilization phase that patients had to successfully
complete to be eligible for randomization. During this run-in
period, the patients’ background therapy for heart failure was
optimized. Background therapy consisted of digoxin and di-
uretic drugs in the PROVED trial and digoxin, diuretic drugs
and angiotensin-converting enzyme (ACE) inhibitors in the
RADIANCE study. Serum digoxin concentration was obtained
on several occasions, and dose adjustments were made in an
attempt to achieve a serum digoxin concentration of 0.9 to
2.0 ng/ml for at least 2 weeks before randomization. The
ACE inhibitor (RADIANCE) and diuretic drug doses
(RADIANCE and PROVED) had to be unchanged for
4 weeks before randomization. Treadmill exercise time had to
be between 2 and 12 min on the initial and final tests, and
exercise duration could not differ by $60 s on the last two tests.
Patients completing this baseline phase were randomized to
continue digoxin therapy or to receive placebo instead of
digoxin while trial-specific background therapy was kept con-
stant for as long as possible during follow-up. After random-
ization, patients were reassessed in detail regarding clinical
status, exercise capacity and ventricular function. Patients were
withdrawn from either study for adverse reactions during
follow-up or if their heart failure worsened sufficiently to
require one of the following therapeutic interventions: change
in background therapy, visit to an emergency room for increas-
ing heart failure or hospital admission for heart failure. A
committee of investigators uninvolved in the care of the
specific study patients and unaware of treatment assignment
classified each withdrawal in the two studies as due to wors-
ening heart failure or an adverse reaction unrelated to heart
failure status.
Entry criteria. Patients $18 years old with mild to moder-
ate symptoms of heart failure (New York Heart Association
functional class II or III) who were in normal sinus rhythm
and had a radionuclide left ventricular ejection fraction
#0.35 and a left ventricular end-diastolic dimension
$60 mm or $34 mm/m2 were considered for enrollment in the
trials. Symptomatic heart failure was documented in all pa-
tients on the basis of evidence of peripheral edema, jugular
venous distension and the presence of interstitial edema or
pulmonary congestion on chest X-ray film. Reasons for exclu-
sion from the two trials were the same and included uncor-
rected primary valvular disease, active myocarditis, obstructive
or restrictive cardiomyopathy, exercise limited by angina,
angina requiring continuous therapy or myocardial infarction
within the previous 3 months. Patients with a history of
supraventricular arrhythmia or sustained ventricular arrhyth-
mia were excluded.
Analysis of end points. Data from the PROVED and
RADIANCE trials were combined for purposes of this
analysis. The primary objectives of both PROVED and
RADIANCE were to compare patients randomized to con-
tinue or discontinue receiving digoxin with respect to the
following particular end points: 1) rates of withdrawal due to
worsening heart failure; 2) time to withdrawal; and 3) changes
in exercise capacity as assessed by treadmill testing or the
6-min walk test. In the present analysis, end points 1 and 2
were considered together in a time-dependent analysis, and
evaluation of exercise capacity was restricted to treadmill
testing. In addition, we compared the change in left ventricular
ejection fraction from randomization to the last measured
value in the study patients.
Heart failure score. Categorization of the degree of clinical
heart failure was based on a heart failure score determined
from patient symptoms, signs and chest X-ray results collected
at the randomization visit. A composite score was computed by
a modification of the method of Carlson et al. (16) as shown in
Table 1. The modified point system and signs and symptoms
were similar to those investigators, except that our score did
not award points for wheezing, S3, bilateral pleural effusion or
a cardiothoracic ratio .0.50, and exertional dyspnea was not
divided into walking and climbing.
Statistical analysis. Various clinical characteristics were
compared at randomization among groups of study patients by
analysis of variance methods or the chi-square test, as appro-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
Dig Cont 5 patients who continued receiving digoxin
regardless of heart failure score
Dig WD Mild 5 patients with mild heart failure (score #2) who
were withdrawn from digoxin
Dig WD Moderate 5 patients with moderate heart failure (score .2)
who were withdrawn from digoxin
PROVED 5 Prospective Randomized Study of Ventricular
Function and Efficacy of Digoxin
RADIANCE 5 Randomized Assessment of Digoxin and
Inhibitors of Angiotensin-Converting Enzyme
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priate. Changes in left ventricular ejection fraction and exer-
cise capacity were compared at the end of the follow-up period
between patient groups using the Student t test or the Wil-
coxon rank-sum test, as appropriate. The risk of treatment
failure was compared between the patient groups by standard
life-table methods (17) and by a multivariate Cox proportional
hazards regression technique (18).
Results
Patient groups. The study analysis was based on the 258
patients in the PROVED and RADIANCE trials who com-
pleted the stabilization period and had a heart failure score
determined at randomization. These patients were classified
into three groups on the basis of treatment assignment and
median heart failure score: 1) patients who continued receiving
digoxin regardless of their heart failure score (Dig Cont);
2) patients withdrawn from digoxin who were defined as having
mild heart failure on the basis of a total score of #2 (Dig WD
Mild); and 3) patients withdrawn from digoxin who were
defined as having moderate heart failure on the basis of a total
score of .2 (Dig WD Moderate). Comparisons of selected
baseline characteristics among these three groups of study
patients revealed them to be similar in most respects (Table 2).
Differences between the groups were noted only for exercise
duration and left ventricular end-diastolic dimension by echo-
cardiography.
Distribution of heart failure score. The individual compo-
nents of the heart failure score at randomization in the three
groups of study patients are shown in Table 3. In the Dig WD
Mild group, 8 (11%) of 75 patients had a heart failure score of
zero, whereas 44 (59%) of 75 had a total score of 1. Dyspnea
on exertion was the predominant symptom in this group and
was present in 59 (79%) of 75 patients. In contrast, no evidence
of rales was found in 72 (96%) of these 75 patients. Only one
patient in the Dig WD Mild group had evidence of right heart
failure at randomization, and only seven had chest X-ray
evidence of pulmonary congestion. In the Dig WD Moderate
group, 20% of the patients had basilar rales, and 33% had
chest X-ray evidence of heart failure.
Treatment failure. Worsening heart failure occurred in 11
(9%) of 122 Dig Cont-group patients. Life-table analysis
demonstrated no relation between heart failure score at ran-
domization and risk of treatment failure in this subset of study
patients (p 5 0.944) (Fig. 2). Treatment failure occurred in 6
(9.5%) of 63 patients in this Dig Cont group who had mild
heart failure by clinical score (#2) compared with 5 (8.5%) of
the remaining 59 patients who had moderate heart failure
score (.2).
Treatment failure occurred in 17 (23%) of the 75 patients
who were in the Dig WD Mild group and in 24 (39%) of the 61
patients in the Dig WD Moderate group. Life-table analysis
demonstrated that patients in the Dig WD Mild group were
significantly more likely to experience worsening heart failure
than those in the Dig Cont group (p 5 0.011) (Fig. 2). Similar
analysis demonstrated that patients in the Dig WD Moderate
group were significantly more likely to experience treatment
failure than either patients in the Dig Cont group (p , 0.001)
or those in the Dig WD Mild group (p 5 0.028) (Fig. 2).
Cox proportional hazards regression analysis evaluated the
Figure 1. Study schema of the PROVED
and RADIANCE studies. After a single-
blind stabilization period, patients were
randomized to continue or discontinue
digoxin with background therapy as indi-
cated. Occurrence of treatment failure was
determined by an events committee that
had no knowledge of treatment assign-
ment. ACEI 5 angiotensin-converting en-
zyme inhibitor; Chg Dig 5 investigator
change in digoxin dose; CXR 5 chest
X-ray film; Echo 5 echocardiogram;
ER 5 emergency room; ETT 5 maximal
treadmill exercise test; HF 5 heart failure;
Hx 5 history; LVEF 5 left ventricular
ejection fraction; Meds 5 medications;
NYHA 5 New York Heart Association
functional class; PE 5 physical examina-
tion; SDC 5 serum digoxin concentration;
6 MinWalk 5 6-min walk test.
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likelihood of treatment failure in the Dig WD Mild and Dig
WD Moderate groups compared with that in the Dig Cont
group after adjustment for left ventricular ejection fraction,
cardiothoracic ratio and ACE inhibitor use determined at
randomization (Table 4). This multivariate analysis demon-
strated that both the Dig WD Mild (p 5 0.002) and Dig WD
Moderate groups (p , 0.001) had a significantly greater risk of
treatment failure than the Dig Cont group (Table 4). In
addition, the multivariate modeling suggested that patients in
the Dig WD Moderate group were significantly more likely to
Table 1. Heart Failure Score Computation
Point
Value Dyspnea
Standing HR
(beats/min) Rales Right HF
Chest X-Ray
Findings
1 Exertional 91–110 Base(s) only JVP .6 cm H2O Upper zone flow redistribution
2 Nocturnal .110 .Base(s) JVP .6 cm H2O 1 edema
or hepatomegaly
Interstitial edema
3 Orthopnea — — — Alveolar edema or interstitial
edema with pleural effusions
4 At rest — — — —
Max points/
category
4 2 2 2 3
Heart failure (HF) score is the total sum of the points awarded, up to the maximum (Max), for each of the five
categories. The highest possible score, equal to the sum of the maximal number of points in each category is 13 and
corresponds to the most severe symptomatic state of heart failure. HR 5 heart rate; JVP 5 jugular venous pulse; — 5
not applicable.
Table 2. Baseline Clinical Characteristics in the Three Groups of
Study Patients
Dig
Cont
Group
(n 5 122)
Digoxin Withdrawal
p
Value*
Dig WD
Mild
Group
(n 5 75)
Dig WD
Moderate
Group
(n 5 61)
Age (yr) 63 6 1.0 62 6 1.4 60 6 1.6 0.293
Male/female 94/28 59/16 51/10 0.587
Etiology 0.333
Ischemic 76 48 32
Nonischemic 46 27 29
Duration of HF (yr) 4.3 6 0.5 3.3 6 0.4 3.9 6 0.6 0.245
HF score
0–1 36 52 0
2 27 23 0
3 29 0 34
$4 30 0 27
Median 2.0 1.0 3.0
SDC (ng/ml) (wk 8) 1.2 6 0.0 1.1 6 0.1 1.1 6 0.1 0.220
Supine HR (beats/min) 76 6 1.1 74 6 1.3 78 6 1.7 0.268
Supine SBP (mm Hg) 127 6 1.6 127 6 2.2 124 6 2.3 0.432
LVEF (U) 26 6 0.9 30 6 1.1 27 6 1.3 0.053
LVEDd (mm) 69 6 1.0 66 6 0.9 70 6 1.1 0.033
CT ratio 0.53 6 0.01 0.52 6 0.01 0.54 6 0.01 0.137
Median ex time (s) 495 609 408 ,0.001
*Reflects overall differences between patient groups assessed by analysis of
variance methods or chi-square statistic, as appropriate. Data presented are
mean value 6 SEM, median or number of patients where appropriate. CT 5
cardiothoracic; Dig Cont 5 patients who continued receiving digoxin regardless
of heart failure (HF) score; Dig WD Mild 5 patients with mild heart failure
(score #2) in whom digoxin was withdrawn; Dig WD Moderate 5 patients with
moderate heart failure (score .2) in whom digoxin was withdrawn; HR 5 heart
rate; LVEDd 5 left ventricular end-diastolic dimension; LVEF 5 left ventricular
ejection fraction; SBP 5 supine blood pressure; SDC 5 serum digoxin concen-
tration taken after 4 to 8 weeks (randomization visit) of stabilization.
Table 3. Components of Heart Failure Score in the Patient Groups
Digoxin Cont
Group
(n 5 122)
Digoxin Withdrawal
Dig WD
Mild Group
(n 5 75)
Dig WD
Moderate Group
(n 5 61)
Total HF score (%)
0 4 11 0
1 25 59 0
2 22 31 0
3 24 0 56
$ 4 25 0 44
Dyspnea (%)
0 5 none 8 17 0
1 5 exertional 53 79 10
2 5 nocturnal 6 4 7
3 5 orthopnea 31 0 82
4 5 at rest 3 0 2
Standing HR (%)
0 ,91 beats/min 72 84 74
1 5 91–110 beats/min 25 16 25
2 .110 beats/min 3 0 1
Rales (%)
0 5 no rales 90 96 80
1 5 bases only 10 4 20
2 .bases 0 0 0
Right HF (%)
0 5 not present 91 99 90
1 5 JVP .6 cm H2O 3 0 3
2 .6 cm H2O1edema or
hepatomegaly
6 1 7
Chest X-ray abnormality (%)
0 5 none present 72 91 67
1 5 upper zone redistribution 19 8 15
2 5 interstitial edema 6 1 13
3 5 alveolar edema 3 0 5
Data presented are percent of patients; zero indicates absence findings (see
Table 1). Abbreviations as in Table 2.
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experience treatment failure than patients in the Dig WD Mild
group (p 5 0.026). Finally, multivariate analysis demonstrated
that patients in both the Dig WD Mild (p 5 0.001) and Dig
WD Moderate (p , 0.001) groups were significantly more
likely to deteriorate than patients in the Dig Cont group after
adjustment for baseline differences in exercise duration and
left ventricular end-diastolic diameter.
Ventricular function and exercise capacity. Figure 3 dem-
onstrates the change in left ventricular ejection fraction during
the course of the follow-up period in the three patient groups.
Left ventricular ejection fraction declined to a significant and
similar degree in the Dig WD Mild and Dig WD Moderate
groups compared to the Dig Cont group (both p , 0.001).
Changes in exercise duration during maximal treadmill exer-
cise testing in the three patient groups are shown in Figure 4.
At the final study visit, exercise duration was significantly less
in patients in the Dig WD Mild (p 5 0.009) and Dig WD
Moderate (p , 0.001) groups compared to Dig Cont patients.
Exercise capacity also deteriorated to a significantly greater
degree in the Dig WD Moderate group compared to the Dig
WD Mild group (p 5 0.005).
Discussion
We investigated the risk of clinical deterioration during
digoxin withdrawal in patients with mild heart failure due to
left ventricular systolic dysfunction. We found that these
patients were at risk for worsening heart failure even though
they had few or no symptoms or signs typical of congestive
heart failure at randomization. Other clinical indexes also
demonstrated that patients with mild heart failure deteriorated
during digoxin withdrawal. They experienced a significant
reduction in exercise capacity and left ventricular ejection
fraction after discontinuing digoxin compared with patients
maintained on this drug. Patients in the Dig WD Mild group
remained at risk of worsening heart failure compared with
patients in the Dig Cont group after adjusting for baseline
ACE inhibitor use, cardiothoracic ratio and left ventricular
ejection fraction.
Our analysis also suggested that patients with moderate
clinical evidence of heart failure were at even greater risk of
treatment failure during digoxin withdrawal. Patients in the
Dig WD Moderate group were more likely to experience
Figure 2. Likelihood of deterioration of heart failure (HF)
status in patients continuing digoxin therapy (Dig Cont’d)
who had mild or moderate heart failure by clinical score
versus patients withdrawn from digoxin who had mild (Dig
WD Mild) or moderate heart failure (Dig WD Moderate) by
the same score criteria. Life-table analysis revealed no differ-
ence in the risk of treatment failure by heart failure score
category in patients who continued receiving digoxin (p 5
0.944). The risk of worsening was significantly greater in
patients with mild heart failure who were withdrawn from
digoxin than in all patients who continued receiving digoxin
(p 5 0.011). Patients withdrawn from digoxin who had
moderate heart failure were significantly more likely to expe-
rience treatment failure during follow-up than either patients
who continued receiving digoxin (p , 0.001) or patients in the
mild heart failure group (p 5 0.028).
Figure 3. Changes in left ventricular ejection fraction (LVEF) from
randomization to final study visit in patients who continued receiving
digoxin (Dig Cont’d) versus patients withdrawn from digoxin who had
either mild (Dig WD Mild) or moderate heart failure (Dig WD
Moderate) by clinical score. Left ventricular ejection fraction declined
to a similar degree in both groups of patients who were withdrawn
from digoxin, and both of these groups had a significant reduction in
ejection fraction compared with patients who continued receiving
digoxin.
Table 4. Adjusted Risk of Treatment Failure: Mild and Moderate
Patient Groups Versus Digoxin-Continued Patient Group
Patient Group
Hazard Ratio
(95% CI)
p
Value*
Dig WD Mild 3.50 (1.58–7.76) 0.002
Dig WD Moderate 7.30 (3.43–15.4) ,0.001
Dig WD Mild vs. Dig
WD Moderate
0.028
*Based on a Cox proportional hazards model that adjusted for left ventric-
ular ejection fraction, cardiothoracic ratio and angiotensin-converting enzyme
inhibitor use at randomization. CI 5 confidence interval; other abbreviations as
in Table 2.
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treatment failure and a deterioration in exercise capacity than
patients in either the Dig WD Mild group or the Dig Cont
group. In contrast, a similar reduction in left ventricular
ejection fraction occurred in patients with mild and moderate
heart failure who were withdrawn from digoxin.
Previous work. Our work both confirms and extends the
observations originally made by Lee et al. (4) and Guyatt et al.
(6). We found that patients with higher heart failure scores
were indeed more likely to worsen than those with few or no
symptoms. However, in contrast to these investigators, we
found a significant risk of worsening heart failure even in
patients with few or no symptoms at the time of randomization.
A number of explanations may account for the differences
between our results and those of previous investigators. Our
patients were characterized by significant left ventricular sys-
tolic dysfunction and cardiomegaly. Whether worsening during
digoxin withdrawal would be found in patients with few or no
current symptoms of heart failure and preserved left ventric-
ular systolic function remains to be determined. Data from the
Digitalis Investigation Group (DIG) trial (13) may provide
important information on this point.
Our results are in agreement with the findings of van
Veldhuisen et al. (19) in a subgroup of patients with mild heart
failure studied in the Dutch Ibopamine Multicenter Trial
(DIMT). This subgroup was composed of patients in the trial
who were not receiving therapy for heart failure at study entry.
Although details of the clinical heart failure score are not
given, 91% of the patients were in functional class II, and only
9% were functional class III at the time of randomization.
During the 6-month follow-up period, patients randomized to
digoxin therapy had improved exercise tolerance and reduced
plasma norepinephrine concentrations compared with patients
randomized to placebo.
Study limitations. Our findings must be regarded with
appropriate caution because investigation of patients with mild
heart failure by clinical score was not a prespecified analysis of
either study design. The follow-up period was limited to 12
weeks in the PROVED and RADIANCE studies. The risk of
clinical worsening after a longer period of digoxin discontinu-
ation in patients with mild heart failure remains to be deter-
mined.
Conclusions. Patients with mild evidence of heart failure
were at risk of clinical worsening during digoxin withdrawal.
They experienced significant deterioration of exercise capacity
and left ventricular ejection fraction and were more likely to
develop worsening heart failure than patients maintained on
digoxin. Our findings support the use of digoxin therapy in
patients with left ventricular systolic dysfunction even when
only a few signs or symptoms of heart failure are present.
We gratefully acknowledge the efforts in manuscript preparation provided by
Tyler Joscelyn.
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